glp-1 for ckd Renal Outcomes of Receptor Agonists and Tirzepatide Across Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review | Diabetes Therapy semaglutide and renal failure Effects

cost accumulates rapidly

Poirier et al

In hereditary or acquired metabolic defects, an initial intravenous bolus of 50 mg/kg may be administered over two to three minutes, followed by maintenance doses of 50 mg/kg every six hours or continuous infusion to achieve a total daily exposure of up to 300 mg/kg in critical illness

10.1038/nrm.2017.132 28 KellyB

While most of these employers currently cover these drugs for diabetes, fewer (67%) cover them for weight loss

Sometimes, the hesitancy is from the patient themselves, she said, not wanting to give themselves an injection or not wanting to take a treatment that might be lifelong, which is understandable for a 12-year-old or even an 18-year-old. But researchers also noted disparities in GLP-1 prescribing